Key regions: United States, Europe, Brazil, Japan, United Kingdom
Bronchodilator Drugs are gaining popularity in Myanmar due to the increasing prevalence of respiratory diseases.
Customer preferences: Myanmar has a high prevalence of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). As a result, there is a high demand for bronchodilator drugs that help in opening up the airways and making breathing easier. Customers in Myanmar prefer bronchodilator drugs that are affordable and effective in managing their respiratory conditions.
Trends in the market: The Bronchodilator Drugs market in Myanmar is growing steadily due to the increasing prevalence of respiratory diseases. The market is dominated by international pharmaceutical companies that offer a wide range of bronchodilator drugs. The demand for combination bronchodilator drugs that offer both short-acting and long-acting relief is increasing in Myanmar. Customers are also increasingly opting for inhalers over traditional oral medications due to the convenience and effectiveness of inhalers.
Local special circumstances: Myanmar is a developing country with a low-income population. As a result, affordability is a key factor that influences customer preferences in the Bronchodilator Drugs market. The government of Myanmar is taking steps to improve the availability and affordability of essential medicines, including bronchodilator drugs. The government has also implemented a universal healthcare program that provides basic healthcare services to the population.
Underlying macroeconomic factors: Myanmar's economy is growing at a steady pace, driven by foreign investment in the manufacturing and services sectors. The healthcare sector in Myanmar is also growing, driven by increasing demand for healthcare services due to the high prevalence of diseases. The government of Myanmar is investing in the healthcare sector to improve the quality and availability of healthcare services. However, the healthcare infrastructure in Myanmar is still underdeveloped, which limits access to healthcare services in some parts of the country.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
